Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review
By Adria Calatayud
Roche Holding said a blood test for earlier diagnosis of Alzheimer's disease it is developing together with Eli Lilly will get an expedited review by the U.S. Food and Drug Administration.
The Swiss pharmaceutical giant said Thursday that the Elecsys pTau217 test received the so-called breakthrough device designation from the FDA, a program designed to accelerate development and review of medical devices.
Roche said the test relies on a biomarker that has shown the ability to distinguish Alzheimer's disease from other neurodegenerative disorders and strong performance relative to other biomarkers in research settings.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 11, 2024 01:33 ET (05:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing